• Explore /
  • Poster
  • / Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.

Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.

Abstract Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Hiroyuki Nishiyama , Shahrokh F. Shariat , Gary Steinberg , Ashish M. Kamat , Shaheen Riadh Alanee , Kijoeng Nam , Kentaro Imai , Ekta Kapadia , Noah M. Hahn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03711032

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS722)

DOI

10.1200/JCO.2024.42.4_suppl.TPS722

Abstract #

TPS722

Poster Bd #

M22

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: Girish S. Kulkarni

First Author: Neal D. Shore

First Author: Ashish M. Kamat